AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
ANI Pharmaceuticals, Inc.
Video analysis: ANIP
All videosNo video analysis for this stock yet. Request one from our team.
News: ANIP
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown of
ANI Pharmaceuticals to Present at September Investor Conferences
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutical company's stock, valued at approximately $2,226,000. Aurora Investment Counsel owned 0.12% of ANI Pharmaceuticals at the end of
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
